Disease · MONDO_0000548

ovarian clear cell cancer

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. ovarian clear cell cancer. Diseases, record MONDO_0000548. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0000548

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: ovarian clear cell cancer; Open Targets
Open Targets ID: MONDO_0000548; Open Targets
Other names: malignant ovarian clear cell neoplasm, malignant ovarian clear cell tumor, malignant ovarian clear cell tumour; Open Targets
Disease Ontology: DOID:0050934; Disease Ontology
NCI Thesaurus: C40077; NCI Thesaurus
Highest stage of its drugs: Phase 2, for 15 of its 17 drugs, from ClinicalTrials.gov; Open Targets

Drugs17

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NIRAPARIB	CHEMBL1094636	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
PACLITAXEL	CHEMBL428647	Small molecule	Phase 2	ClinicalTrials.gov	2	2	2	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CABOZANTINIB	CHEMBL2105717	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
CATEQUENTINIB	CHEMBL4303201	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
DOSTARLIMAB	CHEMBL4298124	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
ETIGILIMAB	CHEMBL4298205	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
IPILIMUMAB	CHEMBL1789844	Antibody	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
NILOTINIB	CHEMBL255863	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 17

See all 17 drugs

Targets28

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
PDCD1	Programmed cell death protein 1	4	Programmed cell death protein 1 antagonist; Programmed cell death protein 1 inhibitor	Phase 2	https://conductscience.org/library/genes/5133	Drugs and targets
PARP1	Poly [ADP-ribose] polymerase 1	3	Poly [ADP-ribose] polymerase-1 inhibitor	Phase 2	https://conductscience.org/library/genes/142	Drugs and targets
PARP2	Poly [ADP-ribose] polymerase 2	3	Poly [ADP-ribose] polymerase 2 inhibitor	Phase 2	https://conductscience.org/library/genes/10038	Drugs and targets
KDR	Vascular endothelial growth factor receptor 2	2	Vascular endothelial growth factor receptor 2 inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
ABL1	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor; Tyrosine-protein kinase ABL inhibitor	Phase 2	https://conductscience.org/library/genes/25	Drugs and targets
BCR	Bcr/Abl fusion protein	1	Bcr/Abl fusion protein inhibitor	Phase 2	https://conductscience.org/library/genes/613	Drugs and targets
CTLA4	Cytotoxic T-lymphocyte protein 4	1	Cytotoxic T-lymphocyte protein 4 inhibitor	Phase 2	https://conductscience.org/library/genes/1493	Drugs and targets
FLT4	Vascular endothelial growth factor receptor 3	1	Vascular endothelial growth factor receptor 3 inhibitor	Phase 2	https://conductscience.org/library/genes/2324	Drugs and targets
KIT	Mast/stem cell growth factor receptor Kit	1	Stem cell growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3815	Drugs and targets
MET	Hepatocyte growth factor receptor	1	Hepatocyte growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/4233	Drugs and targets

1 to 10 of 28

See all 28 targets

Trials10

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT03955471	Study to Evaluate the Efficacy and Safety of the Combination of Niraparib and Dostarlimab (TSR-042) in Participants With Platinum Resistant Ovarian Cancer	Phase 2	41	2022-09-10	Ovarian Neoplasms	DOSTARLIMAB, NIRAPARIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02315430	Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer	Phase 2	13	2020-03-10	Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma	CABOZANTINIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT02834013	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors	Phase 2	798		Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma, Adrenal Gland Pheochromocytoma, Anal Canal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Angiosarcoma, Apocrine Neoplasm, Appendix Mucinous Adenocarcinoma, Bartholin Gland Transitional Cell Carcinoma, Basal Cell Carcinoma, Bladder Adenocarcinoma, Breast Metaplastic Carcinoma, Cervical Adenocarcinoma, Cholangiocarcinoma, Chordoma, Colorectal Squamous Cell Carcinoma, Desmoid Fibromatosis, Endometrial Transitional Cell Carcinoma, Endometrioid Adenocarcinoma, Esophageal Neuroendocrine Carcinoma, Esophageal Undifferentiated Carcinoma, Extrahepatic Bile Duct Carcinoma, Extramammary Paget Disease, Fallopian Tube Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fibromyxoid Tumor, Gallbladder Carcinoma, Gastric Neuroendocrine Carcinoma, Gastric Squamous Cell Carcinoma, Gastric Undifferentiated Carcinoma, Gastrointestinal Stromal Tumor, Gestational Trophoblastic Tumor, Giant Cell Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Intestinal Neuroendocrine Carcinoma, Intrahepatic Cholangiocarcinoma, Lung Neuroendocrine Tumor, Lung Sarcomatoid Carcinoma, Major Salivary Gland Carcinoma, Malignant Neoplasm of Unknown Primary, Malignant Odontogenic Neoplasm, Malignant Peripheral Nerve Sheath Tumor, Malignant Solid Neoplasm, Malignant Testicular Sex Cord-Stromal Tumor, Metastatic Pituitary Neuroendocrine Tumor, Minimally Invasive Lung Adenocarcinoma, Mixed Mesodermal (Mullerian) Tumor, Mucinous Adenocarcinoma, Mucinous Cystadenocarcinoma, Nasal Cavity Adenocarcinoma, Nasal Cavity Carcinoma, Nasopharyngeal Carcinoma, Nasopharyngeal Low Grade Papillary Adenocarcinoma, Nasopharyngeal Undifferentiated Carcinoma, Oral Cavity Carcinoma, Oropharyngeal Undifferentiated Carcinoma, Ovarian Adenocarcinoma, Ovarian Germ Cell Tumor, Ovarian Mucinous Adenocarcinoma, Ovarian Squamous Cell Carcinoma, Ovarian Transitional Cell Carcinoma, Pancreatic Acinar Cell Carcinoma, Pancreatic Neuroendocrine Carcinoma, Paraganglioma, Paranasal Sinus Adenocarcinoma, Paranasal Sinus Carcinoma, Parathyroid Gland Carcinoma, PEComa, Penile Squamous Cell Carcinoma, Peritoneal Mesothelial Neoplasm, Placental Choriocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Pseudomyxoma Peritonei, Rare Disorder, Scrotal Squamous Cell Carcinoma, Seminal Vesicle Adenocarcinoma, Seminoma, Serous Cystadenocarcinoma, Small Intestinal Adenocarcinoma, Small Intestinal Squamous Cell Carcinoma, Spindle Cell Neoplasm, Teratoma With Somatic-Type Malignancy, Testicular Non-Seminomatous Germ Cell Tumor, Thyroid Gland Carcinoma, Tracheal Carcinoma, Transitional Cell Carcinoma, Ureter Adenocarcinoma, Ureter Squamous Cell Carcinoma, Urethral Adenocarcinoma, Urethral Squamous Cell Carcinoma, Vaginal Adenocarcinoma, Vaginal Squamous Cell Carcinoma, Not Otherwise Specified, Vulvar Carcinoma	IPILIMUMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05032040	A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies	Phase 2	170		Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC)	VUDALIMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT05044871	Biomarker-driven Targeted Therapy in Patients With Recurrent Platinum-resistant Epithelial Ovarian Cancer	Phase 2	108		Ovarian Cancer	BEVACIZUMAB, PACLITAXEL, PAMIPARIB, TISLELIZUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04449549	Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel	Phase 2	82		Neoplasms	NILOTINIB, PACLITAXEL	Open Targets' reading of its record	ClinicalTrials.gov
NCT05715216	EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer	Phase 2	23		Ovarian Cancer	ETIGILIMAB, NIVOLUMAB	Open Targets' reading of its record	ClinicalTrials.gov
NCT06617923	Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer	Phase 2	18		Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer	SENAPARIB, TEMOZOLOMIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT05130515	Anlotinib Combined With Niraparib Dual Therapy in Platinum-resistant Recurrent Ovarian Clear Cell Carcinoma.	Phase 2	6		Platinum-resistant Recurrent Clear Cell Ovarian Cancer	CATEQUENTINIB, NIRAPARIB	Open Targets' reading of its record	ClinicalTrials.gov
NCT04611139	Pilot Trial of SP-2577 Plus Pembrolizumab in Select Gynecologic Cancers	Phase 1	0		SCCOHT, Ovarian Clear Cell Tumor, Ovarian Endometrioid Adenocarcinoma, Endometrial Cancer	PEMBROLIZUMAB, SECLIDEMSTAT	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42499790	DERIVED	1	PubMed
41995270	DERIVED	1	PubMed
41892875	DERIVED	1	PubMed
41672597	DERIVED	1	PubMed
40588371	DERIVED	1	PubMed
40402690	DERIVED	1	PubMed
39990653	DERIVED	1	PubMed
39856213	DERIVED	1	PubMed
39583952	DERIVED	1	PubMed
39417692	DERIVED	1	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0000548

GET https://conductscience.org/api/diseases/v1/MONDO_0000548/targets?page=2

API reference For AI assistants